



Five Prime Therapeutics, Inc.  
Investor Relations Department  
Two Corporate Dr, Suite 200  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: FPRX <sup>1</sup>

|                      |                                       |
|----------------------|---------------------------------------|
| Last Trade:          | 28.95                                 |
| Trade Time:          | 4:00 PM ET<br>Friday, May 26,<br>2017 |
| Change:              | -0.84<br>(2.820%)                     |
| Day Range            | 28.81 - 29.81                         |
| 52-Week Range        | 28.17 - 60.98                         |
| Volume               | 201,977                               |
| Market Cap.<br>(\$M) | 833.471                               |
| Shares Out (M)       | 28.790                                |

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Monday, May 15, 2017*

[Five Prime Welcomes Garry Nicholson to Board of Directors](#)

*Thursday, May 4, 2017*

[Five Prime Announces First Quarter 2017 Results and Provides Business Update](#)

*Thursday, April 20, 2017*

[Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting](#)

*Thursday, April 20, 2017*

[Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4](#)

*Monday, April 10, 2017*

[Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis \(PVNS\)](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [First Quarter Financial Results](#)

*Friday, February 24, 2017*  
[Annual Report \(10-K\)](#)

*Friday, March 31, 2017*  
[Definitive Proxy Statement](#)

*Friday, May 5, 2017*  
[Quarterly Report \(10-Q\)](#)

*Friday, November 4, 2016*  
[Quarterly Report \(10-Q\)](#)

*Friday, August 5, 2016*  
[Quarterly Report \(10-Q\)](#)